X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (188) 188
multiple sclerosis (183) 183
index medicus (149) 149
clinical neurology (134) 134
female (111) 111
neurosciences (103) 103
male (99) 99
adult (84) 84
middle aged (77) 77
neurology (76) 76
immunology (48) 48
psychiatry (45) 45
medicine & public health (44) 44
animals (38) 38
research (36) 36
multiple sclerosis - drug therapy (35) 35
aged (31) 31
care and treatment (31) 31
neuroradiology (30) 30
multiple sclerosis - genetics (29) 29
multiple-sclerosis (28) 28
diagnosis (26) 26
pharmacology & pharmacy (26) 26
treatment outcome (26) 26
double-blind (25) 25
patients (25) 25
pathology (24) 24
diagnostic-criteria (23) 23
disease (22) 22
therapy (22) 22
young adult (22) 22
analysis (21) 21
disability (21) 21
inflammation (20) 20
cell biology (19) 19
health aspects (19) 19
immunologic factors - therapeutic use (19) 19
magnetic resonance imaging (19) 19
multiple sclerosis - complications (19) 19
adolescent (18) 18
depression (18) 18
genetic aspects (18) 18
interferon-beta - therapeutic use (18) 18
autoimmunity (17) 17
central-nervous-system (17) 17
gene expression (17) 17
multidisciplinary sciences (17) 17
multiple sclerosis - pathology (17) 17
multiple sclerosis - therapy (17) 17
spasticity (17) 17
apoptosis (16) 16
drug therapy (16) 16
fatigue (16) 16
genetics & heredity (16) 16
germany (16) 16
multiple sclerosis - immunology (16) 16
prevalence (16) 16
prognosis (16) 16
aged, 80 and over (15) 15
allergy and immunology (15) 15
development and progression (15) 15
disease progression (15) 15
experimental allergic encephalomyelitis (15) 15
experimental autoimmune encephalomyelitis (15) 15
prospective studies (15) 15
risk factors (15) 15
usage (15) 15
cancer (14) 14
immunohistochemistry (14) 14
interferon (14) 14
medical research (14) 14
multiple sclerosis - diagnosis (14) 14
quality of life (14) 14
retrospective studies (14) 14
cerebrospinal fluid (13) 13
glatiramer acetate (13) 13
interferon beta (13) 13
medicine (13) 13
medicine, experimental (13) 13
mice (13) 13
multiple sclerosis - physiopathology (13) 13
placebo-controlled trial (13) 13
rats (13) 13
risk (13) 13
antibodies (12) 12
association (12) 12
cohort studies (12) 12
disability evaluation (12) 12
expression (12) 12
genetic predisposition to disease (12) 12
genotype (12) 12
guidelines (12) 12
lymphocytes (12) 12
multiple sclerosis - psychology (12) 12
progressive multifocal leukoencephalopathy (12) 12
severity of illness index (12) 12
t-cells (12) 12
clinically isolated syndrome (11) 11
gene expression profiling (11) 11
genes (11) 11
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Physical Review B - Condensed Matter and Materials Physics, ISSN 0163-1829, 04/1997, Volume 55, Issue 15, pp. 9391 - 9399
The attributes of electron field emission from disordered matrix arrays of carbon nanotubes are studied and found to be quite reproducible in spite of the... 
PHYSICS, CONDENSED MATTER | K UK PHYSICS, CONDENSED MATTER | ELECTRON-EMISSION | MICROTUBULES | COMPOSITE
Journal Article
JOURNAL OF IMMUNOLOGY, ISSN 0022-1767, 04/2019, Volume 202, Issue 8, pp. 2177 - 2187
Inflammasomes are protein complexes that respond to a wide range of pathogens and cellular damage signals. Their activation prompts the caspase-1-mediated... 
SYSTEMIC-LUPUS-ERYTHEMATOSUS | MULTIPLE-SCLEROSIS | GENETIC ASSOCIATION | PERIPHERAL-BLOOD | NLRP3 INFLAMMASOME | IMMUNOLOGY | NOD-LIKE RECEPTOR | BLOOD MONONUCLEAR-CELLS | DECREASED EXPRESSION | PARKINSONS-DISEASE | MIR-146A EXPRESSION
Journal Article
Autoimmunity Reviews, ISSN 1568-9972, 09/2017, Volume 16, Issue 9, pp. 925 - 936
Journal Article
Autoimmunity Reviews, ISSN 1568-9972, 2015, Volume 14, Issue 10, pp. 903 - 913
Journal Article
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 03/2018, Volume 19, Issue 5, pp. 483 - 498
Introduction: Multiple sclerosis (MS) is an immune-mediated and neurodegenerative disease with an unpredictable outcome. Immune-modulatory treatment aims at... 
interferon beta | Multiple sclerosis | ocrelizumab | dimethylfumarate | alemtuzumab | cladribine | fingolimod | teriflunomide | glatiramer acetate | natalizumab | daclizumab | HIGH-YIELD PROCESS | CONTROLLED PHASE-3 | GRANULE CELL NEURONOPATHY | FUMARIC-ACID ESTERS | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | VARICELLA-ZOSTER-VIRUS | INTERFERON-BETA THERAPY | TERM-FOLLOW-UP | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL | DISEASE-MODIFYING THERAPIES | Alemtuzumab - adverse effects | Neoplasms - etiology | Crotonates - metabolism | Alemtuzumab - metabolism | Humans | Immunosuppressive Agents - therapeutic use | Natalizumab - adverse effects | Natalizumab - metabolism | Interferon-beta - therapeutic use | Interferon-beta - adverse effects | Natalizumab - therapeutic use | Fingolimod Hydrochloride - adverse effects | Fingolimod Hydrochloride - therapeutic use | Toluidines - therapeutic use | Toluidines - metabolism | Toluidines - adverse effects | Fingolimod Hydrochloride - metabolism | Crotonates - therapeutic use | Glatiramer Acetate - adverse effects | Cladribine - metabolism | Interferon-beta - metabolism | Cladribine - therapeutic use | Glatiramer Acetate - therapeutic use | Multiple Sclerosis - pathology | Glatiramer Acetate - metabolism | Immunosuppressive Agents - adverse effects | Immunologic Factors - adverse effects | Cladribine - adverse effects | Crotonates - adverse effects | Alemtuzumab - therapeutic use | Immunologic Factors - therapeutic use | Multiple Sclerosis - drug therapy
Journal Article
Journal of Neurology, ISSN 0340-5354, 05/2017, Volume 264, Issue 5, pp. 1032 - 1034
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00415-016-8315-9 
CLINICAL NEUROLOGY | Neurology - history | History, 19th Century | Neurophysiology - history | History, 20th Century | Humans | Germany
Journal Article